AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Feb 11, 2025
30849_dirs_2025-02-11_999be002-744a-4041-ae51-bc75d376298f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-02-09
Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-09 | Common Stock | M | 3437 | — | Acquired | 4409 | Direct |
| 2025-02-09 | Common Stock | M | 4189 | $6.8 | Acquired | 8598 | Direct |
| 2025-02-10 | Common Stock | S | 1894 | $58.3928 | Disposed | 6704 | Direct |
| 2025-02-10 | Common Stock | S | 2295 | $59.3408 | Disposed | 4409 | Direct |
| 2025-02-11 | Common Stock | M | 2031 | — | Acquired | 6440 | Direct |
| 2025-02-11 | Common Stock | S | 1023 | $57.51 | Disposed | 5417 | Direct |
| 2025-02-11 | Common Stock | S | 4 | $57.50 | Disposed | 5413 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-09 | Restricted Stock Units | $ | M | 3437 | Disposed | Common Stock (3437) | Direct | |
| 2025-02-09 | Stock Option (Right to Buy) | $6.8 | M | 4189 | Disposed | 2032-02-08 | Common Stock (4189) | Direct |
| 2025-02-11 | Restricted Stock Units | $ | M | 2031 | Disposed | Common Stock (2031) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.0750 to $58.8900 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $59.1400 to $59.3600 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
F5: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F6: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
F7: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F8: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.